Develops therapeutic proteins to reverse anticoagulation and restore hemostasis.
| Date | Round | Amount |
|---|---|---|
| May 2023 | Series B Leiden biotech VarmX raised a EUR30M Series B2 led by Sound Bioventures, with the EIC Fund and existing investors, to advance its anticoagulation-reversal compound. | $32.4M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.